Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUoENDE study of durvalumab plus platinum-based chemotherapy followed by durvalumab plus olaparib in first-line pMMR advanced or recurrent endometrial cancer
2024-514728-17-00Phase 4Authorised
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of durvalumab and olaparib in endometrial cancer (EC), sponsored by AstraZeneca. Primary endpoints: Frequency of adverse events leading to treatment modification, Frequency of immune-mediated adverse events and 1 more. Planned start Dec 2024; status: authorised.
02
Drugs
durvalumabolaparib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2024-514728-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514728-17-00.